Sirolimus Albumin-bound Nanoparticles

DRUG2 trials

Sponsors

Children's Oncology Group, University of Washington

Conditions

Advanced Soft Tissue SarcomaChildhood Solid NeoplasmLocally Advanced Soft Tissue SarcomaMetastatic Soft Tissue SarcomaRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System NeoplasmRefractory Malignant Solid NeoplasmRefractory Primary Central Nervous System Neoplasm

Phase 1

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

CompletedNCT02975882

Children's Oncology GroupChildhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm +2

Start: 2017-08-15End: 2024-12-31Updated: 2025-01-14

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

TerminatedNCT03660930

University of WashingtonAdvanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma

Start: 2019-04-01End: 2024-07-31Updated: 2025-04-30

Related Papers

A Phase 1 Study of <scp>ABI</scp> ‐009 ( <i>Nab</i> ‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including <scp>CNS</scp> Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study <scp>ADVL1514</scp>

Cancer Medicine2024-11-013 citations

A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).

Journal of Clinical Oncology2023-06-01

ADVL1514, a phase 1 study of ABI-009 (nab-sirolimus) in pediatric patients with recurrent or refractory solid tumors, including CNS tumors as a single agent and in combination with temozolomide and irinotecan: A Children’s Oncology Group pediatric early-phase clinical trial network study.

Journal of Clinical Oncology2022-06-011 citations